JET Enhanced Thrombectomy Intervention


Evaluate real world patient outcomes after treatment of acute and non-acute upper and lower extremity venous and arterial thrombosis with the JETi Thrombectomy System.

Full Title of Study: “JET Enhanced Thrombectomy Intervention – JETi Registry”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2022

Detailed Description

The JETi Registry is an open label, prospective, non-randomized, multi-center observational registry including 250 patients who meet eligibility from up to 30 sites worldwide. Patient participation will be 12 months including post procedure follow-up contact at 10 days, 3, 6 and 12 months. The study duration is estimated at 36 months.


  • Device: JETi Thrombectomy System
    • Thrombectomy

Arms, Groups and Cohorts

  • Deep Vein Thrombosis
    • Patients presenting with deep vein thrombosis for treatment
  • Limb Ischemia
    • Patients presenting with limb ischemia
  • Hemodialysis Access
    • Patients presenting with thrombosed hemodialysis access for treatment
  • Other Thrombotic Conditions
    • Patients presenting with a thrombotic condition other than deep vein thrombosis, limb ischemia or thrombosed hemodialysis access for treatment

Clinical Trial Outcome Measures

Primary Measures

  • Change in Percent of Occlusion From Baseline to Final Angiogram/Venogram
    • Time Frame: 0 days
    • From the Index Procedure’s Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms/venograms, each vessel will be assigned a value by the independent core lab. Complete occlusion (>90% occlusion) Substantial occlusion (50-90% occlusion OR <50% occlusion and >3cm in length) Partial occlusion (<50% occlusion AND <3cm in length) Patent/Normal (without visible thrombus or occlusion)
  • Rethrombosis
    • Time Frame: up to 12 Month Follow Up
    • The number of patients affected by rethrombosis of the treated vessels (first episode) throughout a 12 Month Follow-Up.

Secondary Measures

  • Technical Success
    • Time Frame: 0 days
    • Change in the degree of occlusion from baseline to final angiogram

Participating in This Clinical Trial

Inclusion Criteria

  • Patient has been treated for acute/sub-acute thrombosis in the peripheral vascular system with any of the JETi® Peripheral Thrombectomy System Catheters
  • Patient has provided appropriate consent/authorization per the site's institutional policy and procedure.
  • Age ≥ 18 years.

Exclusion Criteria

  • Patient has previously been enrolled in JETi Registry in the last 12 months.
  • Current participation in another drug or device trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Walk Vascular LLC
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.